ImmunoGen Gets Positive Data on New Drug

[cnbc 3000047843]

In this volatile market, investors need stocks that will keep them interested even when things are at their most bleak, says Mad Money host, Jim Cramer. Discussing the next-generation of cancer treatments with biotech developer, Daniel Julies, ImmunoGen CEO.

With a reach of over 400 million CNBC is ground zero for traders and investors monitoring the financial world.

Video © and provided by CNBC.

Be the first to comment

Leave a Reply